Serono spin­off Ca­lyp­so Biotech be­comes res­i­dent at J&J's Eu­ro­pean in­cu­ba­tor, rais­es $22M+ in Se­ries A

7 years ago
Financing
Startups

J&J steps up along­side Ab­b­Vie to part­ner with fast-grow­ing Mor­phic on its small mol­e­cule ap­proach to in­te­grins

7 years ago
R&D
Pharma

FDA cites an ‘on­go­ing re­view’ for Pfiz­er's block­buster Xel­janz, with im­pli­ca­tions for the class

7 years ago
Pharma

Kalei­do sets terms for $100M IPO; Mallinck­rodt touts pos­i­tive PhI­II GVHD da­ta, cuts tri­al short

7 years ago
News Briefing

Pelo­ton rais­es a mon­ster $150M in lat­est round, as lead drug heads for piv­otal tri­al

7 years ago
Financing

Ap­ply­ing CRISPR to Duchenne, Duke re­searchers spot­light 1-year mouse da­ta in Sarep­ta-spon­sored study

7 years ago
Discovery

IP trou­ble de­fers launch of Novo's long-act­ing he­mo­phil­ia ther­a­py

7 years ago
Pharma

Deaths spur par­tial hold for Xen­cor’s CD3 bis­pe­cif­ic for leukemia, part­nered with No­var­tis in $2.5B deal

7 years ago
R&D

Stem cell ther­a­pies for space mis­sions? Pluris­tem joins forces with NASA to com­bat space-re­lat­ed ail­ments

7 years ago
R&D
Pharma

Backed by Or­biMed and J&J to build pre­ci­sion bac­te­ria-killing tool, Bio­mX adds a slate of in­vestors in $32M Se­ries B

7 years ago
Financing
Startups

Pfiz­er drops 10 mg dose of best-sell­ing Xel­janz as study spot­lights car­dio safe­ty is­sue, high­er rate of deaths

7 years ago
R&D

Mer­ck’s PhI­II liv­er can­cer study for Keytru­da fails on two key end­points, just three months af­ter the FDA gave it ...

7 years ago
R&D

Strike 3: Vi­cal ax­es its on­ly re­main­ing clin­i­cal pro­gram, com­plet­ing a tri­fec­ta of dis­as­ters

7 years ago
R&D

Stock ac­tivists fire back at Al­ler­gan’s de­fen­sive moves, push for a com­pa­ny sale

7 years ago
Deals

FDA cau­tions over young donor blood trans­fu­sions to treat ag­ing, mem­o­ry loss

7 years ago
Pharma

Ab­b­Vie scores speedy re­view for RA drug upadac­i­tinib; Mer­ck KGaA wins CRISPR patent

7 years ago
News Briefing

Is­rael's Im­mune Phar­ma waves the white flag af­ter fail­ing to se­cure deals for in­flam­ma­tion drug

7 years ago
R&D

Ex-Cel­gene CEO Bob Hug­in makes a leap back in­to biotech, join­ing an em­bat­tled Al­ler­gan's board

7 years ago
People

As gener­ic com­pe­ti­tion stut­ter sales of top on­col­o­gy drugs, Roche se­cures speedy re­view for pair of ex­per­i­men­tal ...

7 years ago
Pharma

In­ter­cept scores a mixed win on NASH Phase III sweep­stakes, plans mar­ket­ing pitch

7 years ago
R&D

Dogged by safe­ty is­sues, Eli Lil­ly and Pfiz­er tout their lat­est PhI­II for an­ti-NGF pain drug tanezum­ab

7 years ago
R&D

Throw­ing in the tow­el, trou­bled an­tibi­ot­ic mak­er Ar­a­digm files for Chap­ter 11

7 years ago
R&D

In a pi­o­neer­ing re­gen­er­a­tive med study, sci­en­tists get a green light to test iPS cells for spinal cord dam­age

7 years ago
R&D

French biotech In­ven­ti­va's lead drug stum­bles in sys­temic scle­ro­sis study, ahead of NASH read­out

7 years ago
R&D
First page Previous page 958959960961962963964 Next page Last page
A service from the Financial Times